SCHEMBL27218704

SCHEMBL27218704

COc1ccc(-c2cc(CSc3nc(C)cc(N)n3)on2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 6/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.47
▸ NPC1 O15118 4/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ MAPT P10636 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MIF P14174 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ LMNA P02545 3/20 0.43
▸ HTT P42858 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ DYRK1A Q13627 1/20 0.43
▸ IGF1R P08069 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218798 0.86 RAB9A (0.58) SMN1; SMN2NPC1RAB9AMAPTL3MBTL1
SCHEMBL27218769 0.82 MAPT (0.50) SMN1; SMN2NPC1RAB9AMAPTL3MBTL1
SCHEMBL27218874 0.80 HTT (0.69) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL27218684 0.76 NPSR1 (0.51) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL27218807 0.76 RAB9A (0.61) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL27218721 0.76 RAB9A (0.44) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL31494329 0.75 HTT (0.52) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL27218829 0.75 HTT (0.52) SMN1; SMN2NPC1RAB9AMAPTTDP1
SCHEMBL2898452 0.72 NOTUM (0.64) SMN1; SMN2NPC1RAB9AMAPTL3MBTL1
SCHEMBL1566577 0.72 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 PTGS2 1505/4885SMN1; SMN2 1802/4885NPC1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback